Jaguar Health Inc (NASDAQ:JAGX) was the target of a significant decline in short interest during the month of June. As of June 30th, there was short interest totalling 99,300 shares, a decline of 26.9% from the May 30th total of 135,900 shares. Based on an average daily trading volume, of 321,400 shares, the short-interest ratio is presently 0.3 days. Currently, 0.5% of the company’s shares are sold short.

NASDAQ JAGX traded down $0.21 during trading on Friday, reaching $3.20. 377,200 shares of the stock traded hands, compared to its average volume of 208,381. The company has a market capitalization of $5.06 million, a price-to-earnings ratio of -0.02 and a beta of 0.70. The firm’s 50-day moving average is $3.85. The company has a current ratio of 0.30, a quick ratio of 0.18 and a debt-to-equity ratio of 0.02. Jaguar Health has a fifty-two week low of $3.16 and a fifty-two week high of $175.00.

Jaguar Health (NASDAQ:JAGX) last issued its quarterly earnings data on Tuesday, May 21st. The biotechnology company reported ($12.59) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($13.29) by $0.70. The firm had revenue of $1.59 million during the quarter, compared to analysts’ expectations of $2.20 million. Jaguar Health had a negative net margin of 667.59% and a negative return on equity of 372.84%. As a group, equities analysts anticipate that Jaguar Health will post -6.07 EPS for the current fiscal year.

A number of research firms recently weighed in on JAGX. ValuEngine downgraded shares of Zumiez from a “hold” rating to a “sell” rating in a research note on Tuesday, July 2nd. HC Wainwright set a $10.00 price target on shares of Jaguar Health and gave the stock a “buy” rating in a research note on Tuesday, July 2nd. Finally, Zacks Investment Research raised shares of Booz Allen Hamilton from a “hold” rating to a “buy” rating and set a $71.00 price target for the company in a research note on Friday, June 28th.

About Jaguar Health

Jaguar Health, Inc, a commercial stage natural-products pharmaceuticals company, focuses on developing gastrointestinal products for human prescription use and animals worldwide. The company, through its wholly-owned subsidiary, Napo Pharmaceuticals, Inc, focuses on developing and commercializing proprietary human gastrointestinal pharmaceuticals for the global marketplace from plants used traditionally in rainforest areas.

Read More: How to interpret a stock’s beta number

Receive News & Ratings for Jaguar Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jaguar Health and related companies with's FREE daily email newsletter.